Pallas Capital Advisors LLC Acquires New Stake in West Pharmaceutical Services, Inc. $WST

Pallas Capital Advisors LLC acquired a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, HoldingsChannel reports. The firm acquired 6,349 shares of the medical instruments supplier’s stock, valued at approximately $2,279,000.

Several other institutional investors have also recently added to or reduced their stakes in WST. Elyxium Wealth LLC purchased a new position in West Pharmaceutical Services in the 4th quarter valued at about $25,000. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth about $25,000. Cornerstone Planning Group LLC grew its holdings in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 50 shares in the last quarter. Bayban acquired a new position in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $27,000. Finally, Private Trust Co. NA raised its position in shares of West Pharmaceutical Services by 156.4% in the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 61 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 0.8%

Shares of WST opened at $346.69 on Tuesday. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00. The firm has a market capitalization of $24.40 billion, a P/E ratio of 44.39, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock’s fifty day simple moving average is $347.00 and its 200 day simple moving average is $296.89.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is presently 11.27%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on WST. Morgan Stanley raised their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Citigroup boosted their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a report on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.